Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Orexo in connection with the divestment of the US rights to Zubsolv
Mandate

Vinge has advised Orexo in connection with the divestment of the US rights to Zubsolv

January 14, 2026

Vinge has advised Orexo in relation to Swedish law in connection with the divestment of the US rights to Zubsolv to Dexcel Pharma USA.

The purchase price amounted to USD 91 million. Furthermore, Orexo is entitled to a contingent consideration of up to USD 16.8 million, based on future Zubsolv net sales during 2026 and 2027. Steptoe LLP acted as lead legal counsel in connection with the transaction and Vinge advised Orexo in relation to Swedish law.

Vinge’s team consisted of Rikard Lindahl, Viveka Classon, Kim Bergman Aldevinge and Sara Stålebring.

Related

Vinge advises Morrow Bank in connection with cross-border merger and list change from Oslo Børs to Nasdaq Stockholm

 Vinge has advised Morrow Bank in connection with its reverse cross-border merger, whereby Morrow Bank AB is taking over Morrow Bank ASA. The Norwegian bank was previously listed on the Oslo Stock Exchange which was today transferred to Nasdaq Stockholm. Vinge has previously assisted Morrow Bank in obtaining a Swedish banking licence.
January 12, 2026

Vinge advises Dunlop Aircraft Tyres in connection with its issuance of USD 93 million senior secured bonds

 Vinge has advised Dunlop, in connection with its issuance of senior secured bonds in the amount of USD 93 million, under a total framework of USD 120 million.
January 08, 2026

Vinge advises Stockwik Förvaltning in conjunction with the acquisition of Labino

 Vinge has advised Stockwik Förvaltning in connection with its acquisition of Labino, a world-leading Swedish manufacturer of industrial UV light fixtures.
December 19, 2025